Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zantac 75 slated for first-quarter launch following Dec. 19 approval by FDA.

This article was originally published in The Tan Sheet

Executive Summary

WARNER-LAMBERT BANKING ON ZANTAC's Rx "LEADERSHIP" POSITION to propel Zantac 75 into the competitive OTC H2 antagonist market, the company indicated in a same-day announcement of FDA's approval of the drug for the treatment of heartburn on Dec. 19. Zantac 75 is the third Rx-to-OTC switch H2 antagonist to clear FDA; the ranitidine HCl 75 mg product is slated to launch in the first quarter.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel